We further confirmed the protein expression of RAF1 through Western blot, after the HCC group was divided into two sub-groups according to different responses to sorafenib, which were the complete response (CR), the partial response (PR), the stable disease (SD), and the progressive disease (PD). The gene discussed is RAF1; the disease is hepatocellular carcinoma.